ABSTRACT
INTRODUCTION
Single or double heart valve replacement for endocarditis is a relatively common operation, but triple valve surgery is usually complex and carries a high operative mortality rate and a low 10-year survival rate [Alsoufi 2006] . Patients with mechanical heart valves must follow lifelong warfarin therapy. Warfarin is a difficult drug to manage, however, because of its narrow and controversial therapeutic window and potentially serious side effects.
Despite improvements in operative and myocardialprotection techniques, multiple valve surgery remains challenging. Patients are subjected to long cardiopulmonary bypass and myocardial ischemia times. The operative mortality rate reported after triple valve surgery is high and ranges between 13% and 25% [Galloway 1992; Alsoufi 2006] . Moreover, the replacement of multiple valves exposes the patient to added long-term morbidities related to prosthetic valves, such as thromboembolism, anticoagulation-related hemorrhage, endocarditis, and paravalvular leakage, compared with the replacement of single valves [Brown 1993 ]. Finally, triple valve surgery has been associated with diminished long-term survival, with reported survival rates at 5 years and 10 years of 75% and 61%, respectively [Alsoufi 2006 ]. Lifelong oral anticoagulation therapy is essential for the prevention of thromboembolic events in patients with valves replaced with mechanical valves [Cannegieter 1994 ]. Factors influencing the risk of arterial thromboembolism include valve type (caged ball, caged disk, tilting disk, or bileaflet), valve site (aortic or mitral), and the number of valves replaced [Salem 2004 ]; however, this treatment introduces a risk of severe or fatal bleeding [Levine 1989 ]. The aim of anticoagulation is to balance the lowest risk of bleeding with the lowest risk of thromboembolic complications. The European Society of Cardiology has recommended an INR of 3.0 to 3.5 for mechanical valves in the mitral position, whereas an INR of 2.5 to 3.0 was considered sufficient for mechanical valves in the aortic position [Gohlke-Bärwolf 1995] . The American College of Cardiology and American Heart Association guidelines of 2006 recommend an INR of 2.0 to 3.0 for replacing an aortic valve with a bileaflet mechanical or Medtronic Hall prosthesis in patients with no risk factors. If a patient has risk factors, oral anticoagulants are indicated to achieve an INR of 2.5 to 3.5. After replacement of an aortic valve with other mechanical valves, or after mitral valve replacement, an INR of 2.5 to 3.5 is also recommended [Bonow 2006 ]. This range is associated with an increased risk of bleeding complications. Because of differences in blood coagulation characteristics, Asian
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patients have a greater tendency to bleed during anticoagulation therapy than Western patients. Therefore, the guidelines recommended by the American College of Chest Physicians may not be relevant, and it may not be appropriate to extrapolate data from Western patients to the Chinese population.
We performed a quadruple valve replacement with mechanical valves, combined with correction of complex congenital heart disease, on November 17, 1999. We report here the 11-year follow-up of the patient after valve replacement.
METHODS

Patient and Methods
The patient, a 48-year-old man from Xi'an, Shannxi province, China, was transferred to our hospital after several weeks of progressive dyspnea, lower-extremity edema, and orthopnea on November 12, 1999. He was noted immediately after birth to have a heart murmur, received a diagnosis of having a ventricular septal defect, and underwent no treatment. Three months before transfer to our hospital, the patient suddenly developed a high fever, as high as 39.2C. After broadspectrum antibiotic coverage with ampicillin, gentamicin, and imipenem, the fever was controlled, but heart failure symptoms appeared and progressed quickly. On admission, the patient was tachycardic with an obvious heart murmur. An echocardiography evaluation showed a ventricular septal defect, an obstruction of the right ventricular outflow tract, and endocarditis of the aortic, tricuspid, mitral, and pulmonary valves with severe insufficiency.
We had a great deal of communication with the patient and his family about the risks and benefits of surgery and the possible complications. The patient strongly wanted surgery, and his family gave written consent.
The quadruple valve replacement took place on November 17, 1999. The patient was placed in a supine position, and endotracheal intubation was performed with the patient under general anesthesia. Surgery was performed with the patient on aorto-bicaval cardiopulmonary bypass via a midline sternotomy. The patient's systemic temperature was lowered to 28°C, with myocardial protection being achieved through antegrade cardioplegia introduced directly into the coronary ostia. Intraoperative examination revealed the following: several abnormal muscle bundles that caused the right ventricular outflow tract obstruction; a perimembranous type of ventricular septal defect (size, 2 cm); vegetation (diameter, 1 cm) on the anterior mitral valve leaflet, scattered vegetations on the posterior mitral valve leaflet, and chordal rupture of the anterior mitral valve leaflet; perforation of the anterior tricuspid valve leaflet and a vegetation approximately 1.0 cm in diameter; a vegetation (diameter, 0.7 cm) on the noncoronary aortic valve leaflet, part of the right coronary valve eroded by bacteria, and thickening of the residual valve tissue; scattered vegetations on the pulmonary valve leaflet and part of the valve eroded by bacteria. The aortic valve was excised first, followed by the tricuspid valve, the mitral valve, and the pulmonary root. The excised valves had the classic appearance characteristic of subacute rheumatic endocarditis. First, we relieved the obstruction of the right ventricular outflow tract and repaired the ventricular septal defect. The mitral valve was replaced (27-mm valve, serial no. C411287-B; Carbomedics/Sorin Group, Milan, Italy), followed by the aortic valve (23-mm valve, serial no. 98060372; Baxter, Chicago, IL, USA) and the pulmonary valve (25-mm valve, serial no. C410965-B; Carbomedics). After release of the aortic cross-clamp and rewarming of the patient, the tricuspid valve (29-mm valve, serial no. C395894-B; Carbomedics) was replaced. The total cardiopulmonary bypass time was 210 min, and the cross-clamp time was 149 min.
To realize a satisfactory postoperative cardiac function, we adopted retrograde low-flow infusion with cold oxygenated dilute blood cardioplegia through the coronary sinus. The intraoperative course was otherwise uneventful, and the patient was weaned from cardiopulmonary bypass with small doses of inotropes. Postoperative bleeding required blood transfusion.
Intravenous unfractionated heparin (IVUH) therapy was started on the first postoperative day at 0.5 mg/kg every 6 hours and was adjusted to an activated partial thromboplastin time in the target range of 1.5 to 2.5 times the control. These measurements were repeated as often as necessary, with the last measurement taken before stopping IVUH treatment. Platelet counts were performed daily during the first 3 postoperative days during IVUH treatment. Warfarin therapy was started on the third postoperative day, and the IVUH therapy was stopped.
Warfarin was orally administered at a dosage of 2.5 mg at 5 PM once per day, and the INR was checked daily to maintain INR values of 2.3 to 3.2 for 5 days. The dose was then changed to 2.0 mg, once daily, and the INR was maintained at approximately 2.1 to 2.5 for 5 days. The dose was then reduced to 1.7 mg, once a day, and the INR was maintained at approximately 1.6 to 2.0. After the INR reached the therapeutic range of approximately 1.5 to 2.0, it was checked weekly for 3 weeks and then less often, depending on the stability of the results. The patient was required to be present for outpatient assessment after hospital discharge at the following intervals: 2 times per month during the first 6 months; every 2 months for the succeeding 6 months, and at least 3 times in the following year. 
DISCUSSION
Quadruple valve replacement is complicated and challenging. The patient had underlying myocardial dysfunction because of his multiple valve disease, and he was exposed to prolonged cardiopulmonary bypass and myocardial ischemia. Heart valve replacement for endocarditis is a relatively common operation, but the current case is notable for 2 reasons: (1) All cardiac valves were replaced with mechanical prosthetic heart valves in combination with correction of complex congenital heart disease in a single operation; and (2) the patient, in whom the INR has been maintained between approximately 1.5 and 2.0, has been living for 11 years without any thromboembolic or bleeding complications. To the best of our knowledge, the current report is the first to describe not only successful quadruple valve replacement with mechanical valves combined with correction of complex congenital heart disease for subacute rheumatic endocarditis, but also long-term survival after the surgery.
In 1987, Hossack and colleagues first reported on a patient with rheumatic involvement of all valves with a good longterm outcome. This patient underwent replacement of the aortic, mitral, and pulmonary valves, and because of severe regurgitation, he subsequently underwent replacement of the tricuspid valve as well [Hossack 1987 ]. Seeburger and colleagues also reported on a patient with rheumatic involvement of all valves [Seeburger 2009 ]. With the great medical advances available, especially the use of transesophageal The Heart Surgery Forum #2011-1124 E148 echocardiography in the diagnosis of infective endocarditis, they successfully replaced all cardiac valves in a single operation, and the patient recovered well. Although the cases mentioned above demonstrate that quadruple valve surgery can be performed successfully, previous reports have indicated that triple valve surgery is associated with a high operative mortality rate (ranging between 13% and 25%) and poor long-term survival, with reported survival rates at 5 years and 10 years of 75% and 61%, respectively [Galloway 1992; Alsoufi 2006] . We believe that improved perioperative care, including increased experience with complex surgical procedures, improved myocardial protection, and improved postoperative care contributed to the very good long-term survival observed in our follow-up study. To the best of our knowledge, our patient's survival time after surgery is the longest described among the current reports of quadruple valve replacement.
Patients who undergo valve replacement with mechanical heart valves require lifelong anticoagulation therapy [Cannegieter 1994] . The optimal anticoagulant intensity in patients with mechanical valves is still a matter of debate, however, and several guidelines have been published. In Western countries, the overall incidence of major hemorrhagic complications was still between 1.2 and 5.6 per 100 patient-years, and the rate of occurrence of thromboembolic events was between 0.4 and 6.5 per 100 patient-years [Levine 2001] .
Asians seem to be less vulnerable to thrombotic diseases than Caucasians. The incidence of thromboembolism is low in Japan, despite the less intensive regimen [Kudo 1999] . Most of the current anticoagulation protocols in China are based on clinical results obtained from Western countries. There have been many more anticoagulant-related bleeding complications documented in past years [Sun 2003 ].
It is generally recommended that the intensity of anticoagulation be controlled within an ideal range to minimize hemorrhagic complications [Cortelazzo 1993 ]. The European Society of Cardiology has recommended an INR of 3.0 to 3.5 for mechanical valves in the mitral position, whereas an INR of 2.5 to 3.0 was considered sufficient for mechanical valves in the aortic position [Gohlke-Bärwolf 1995] . The American College of Cardiology and American Heart Association guidelines of 2006 recommend an INR of 2.0 to 3.0 for aortic valve replacement. If a patient has risk factors, oral anticoagulants are indicated to achieve an INR of 2.5 to 3.5 [Bonow 2006 ]. Mori and colleagues, however, found a significant increase in morbidity from bleeding in Japanese patients with an INR >2.5 [Mori 2002 ]. Uetsuka and colleagues investigated their experiences with 1157 Japanese patients with mechanical heart valve prostheses and discovered that the incidence of thromboembolism did not increase, even when the INR was reduced to 1.5 [Uetsuka 2000) . Some domestic institutions have suggested a target INR of 1.5 to 2.0 for Chinese patients [Dong 2003; Zhuang 2004; Zhou 2005 ]. Chenhsu and colleagues in Taipei noted a high incidence of bleeding and fatal hemorrhages among 61 patients with a mean INR of 1.9 [Chenhsu 2000 ]. Zhou and colleagues reported that the linearized rate of bleeding was 5.83 per 100 patient-years but only 0.26 per 100 patient-years for thromboembolism in their study [Zhou 2005] . Therefore, it is more important to focus on preventing the occurrence of bleeding in Chinese patients than on the incidence of thromboembolism. In our hospital, warfarin therapy with an INR range of 1.5 to 2.0 was used for double or multiple valve replacement.
The Early Self-Controlled Anticoagulation Trial II has provided evidence that the INR target can be reduced from a range of 2.5 to 4.5 to a range of 1.8 to 2.8 in patients with aortic valve replacement, and to 2.5 to 3.5 in patients with mitral valve replacement or double valve replacement, without increasing the risk of thromboembolic events [Koertke 2007 ]. Nevertheless, their target INR range is higher than ours, and the goal of self-management is hard to realize in developing countries. In China, the monitoring of INR and subsequent adjustment of the warfarin dosage after hospital discharge is a significant challenge because of geographical restrictions, economic conditions, and a lack of medical knowledge. The fluctuation in the INR in the first 6 months was greater than in other periods, and the risk of developing bleeding complications is highest within the first half year after valve replacement [Eitz 2008 ]. Therefore, following up the patient in the first 6 months after discharge from the hospital is most critical. We suggest that patients be seen at least twice in these defining months.
Our patient made an excellent recovery from a large and complex operation without severe complications. The patient's INR was maintained between 1.5 and 2.0. All 4 mechanical prosthetic heart valves have been working well for the 11 years following the operation. He is in generally good health without any thromboembolic or bleeding complications. This case suggests that with adequate cardiac protection, replacement of all cardiac valves can be accomplished in selected patients with quadruple valve disease. A target INR of 1.5 to 2.0 could be appropriate for Chinese patients who undergo valve replacement with mechanical valves.
